Biora
This article was originally published in The Gray Sheet
Executive Summary
Plans to launch its PrefGel in the third quarter of 1998 following recent FDA clearance, the company says June 3. PrefGel, which is to be used by periodontists for conditioning exposed root surfaces during periodontal surgery, received European approval under the name PrepHgel earlier this year. PrefGel is the company's second dental therapy to reach the market. Its first product, Emdogain, for treatment of intrabony defects, was approved in 1996 ("The Gray Sheet" Oct. 21, 1996, I&W-4)...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.